FrontLab
“The prefrontal cortex as a critical hub for higher cognitive functions: from health to disease”
Embedded Files
The FrontLab, directed by Richard Levy and Emmanuelle Volle, is a research team within the Paris Brain Institute. The general aim of the team is to understand the role and organization of the prefrontal cortex in the control, activation, and inhibition of goal-directed behaviours.
The FrontLab research is organized around two main interacting axes: a cognitive neuroscience axis and a translational research axis.
The Cognitive Neuroscience axis focuses on the neuroscience of high-level cognitive functions, encompassing cognitive control and mind-wandering, inhibitory control and mental flexibility, creativity and reasoning, taking into account the role of attentional and valuation processes.
The translational neuroscience axis focuses on pathologies affecting the frontal lobes (such as fronto-temporal dementia/FTD). Our aim is to refine the phenotype of degenerative prefrontal syndromes, clarifying the underlying mechanisms and neural bases of behavioural disorders such as apathy and disinhibition, and developing new assessment tools and therapeutic approaches to alleviate cognitive and behavioural frontal syndromes.
Our research takes advantage of an interdisciplinary approach combining experimental psychology (developing new cognitive paradigms or tools), ecological settings and human ethological assessment in natural settings, computational modelling network science, and multimodal structural and functional neuroimaging methods, including classical MRI and EEG, but also original approaches we developed particular expertise with (brain lesion studies, network-based connectivity, non-invasive and invasive neurostimulation during awake neurosurgery, recording of intracranial EEG in implanted patients).
Our research program should allow to clarify the cognitive and neural mechanisms of functions "hubing" in the prefrontal cortex, providing a new framework for high-level cognitive functions and complex behaviours (decision-making, planning, reasoning, creativity, moral judgment, social interactions…) and how we can influence them. In the long run, it will hopefully lead to applications in improving diagnostic tools for patients with neurological and psychiatric diseases affecting these brain regions (e.g., Fronto-temporal dementia, brain tumors, stroke, etc.) and developing cognitive training programs.
More specific goals at the first neurocognitive level will be to decipher the associative, controlled, valuative, and attentional cognitive mechanisms involved in high-level cognition and characterize them as emerging from interactive and dynamic brain networks. We will focus on high-level cognitive functions such as creativity, analogical reasoning, abstract thinking, cognitive flexibility or inhibition, and mind-wandering. Some of our specific subgoals will be: 1) To build a new cognitive model of creativity involving decision-making processes, with a valuation component interacting with a memory foraging component and a control component for creative idea generation. 2) To identify the mechanisms of problem-solving and examine how they involve a reorganization of our knowledge; 3) To determine how contextual, attentional, emotional, or individual factors can impact idea generation and problem-solving; 4) To determine the attentional and neural markers of mind-wandering and develop cognitive and brain intervention methods to modulate them. In the longer term, our research should allow us to develop new cognitive tools to profile creative ability in individuals based on the identified mechanisms. We also aim to elaborate cognitive training and neuromodulation programs to act on the identified mechanisms and improve sustained attention, problem-solving, and creative cognition.
More specific goals at the second translational level will be three-folded: 1/ we wish to translate the cognitive assessments (creativity, attentional states, abstract thinking...), including web-based tools developed at the "cognitive neuroscience level" to the clinic: i) to better phenotype (in combination with other biomarkers) our cohorts of neurological diseases (e.g., FTD, Alzheimer Disease), ii) to accurately determine the conversion from pre-symptomatic to disease (in particular, in FTD) and iii) to develop markers that can be used to assess treatment efficacy; 2/ we will further develop an original approach consisting in finding behavioral signatures of frontal behavior dysfunctions (apathy, disinhibition, social cognition impairments...) in natural settings, under structured and controlled scenario and paradigms in ecological situations (either close to a real-life situation in the lab (ECOCAPTURE@lab or CogToolkit Labcom projects) or at home (ECOCAPTURE@home) taking advantages of new technologies (e.g., sensors, smartphones). These behavioral signatures will be used to provide a more objective way to assess behavior, to investigate the neural bases of behavioral disorders and ultimately propose new options to treat behavioral disorders; 3/ we would like to pursue our therapeutical approaches using external neurostimulation (TDCs to attenuate cognitive/behavioral disorders in neurodegenerative diseases and develop new tools based on our cognitive neuroscience expertise (including non-pharmological interventions such as neurofeedback) and ecological, behavioral approach (ECOCAPTURE@work) for rehabilitation programs.
Research topics
Methods
People
Publications
Follow us on twitter!
Page updated
Google Sites
Report abuse